
Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B
Author(s) -
Bai Yunhong,
Wu Xingyao,
Brennan Kathryn M.,
Wang David S.,
D'Antonio Maurizio,
Moran John,
Svaren John,
Shy Michael E.
Publication year - 2018
Publication title -
annals of clinical and translational neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.824
H-Index - 42
ISSN - 2328-9503
DOI - 10.1002/acn3.543
Subject(s) - unfolded protein response , mutant , xbp1 , mutation , wild type , rna splicing , biology , microbiology and biotechnology , genetics , gene , rna
Objective To determine the prevalence of MPZ mutations that cause Charcot Marie Tooth neuropathy type 1B ( CMT 1B) and activate the unfolded protein Response ( UPR ). Background CMT 1B is caused by >200 heterozygous mutations in MPZ , the major protein in peripheral nerve myelin. Mutations Ser63del MPZ and Arg98Cys MPZ cause the mutant protein to be retained in the ER and activate the generally adaptive UPR . Treatments that modulate UPR activation have improved cellular and rodent models of CMT 1B raising the possibility that other MPZ mutations that activate the UPR would also respond favorably to similar treatment. The prevalence of MPZ mutations that activate the UPR is unknown. Methods We developed a dual luciferase reporter assay of Xbp1 splicing using stably transfected RT 4 Schwann cells to assay the ability of cDNA constructs bearing 46 distinct MPZ mutations to activate the UPR . Constructs also carried an HA tag to permit detection of ER retention of mutant proteins. UPR activation and ER retention were correlated with clinical phenotypes. Results Eighteen mutations demonstrated ER retention and UPR activation to a similar degree as Ser63del and Arg98Cys MPZ . Thirty‐five of the mutations activated the UPR > 1.5 fold compared to that of wild‐type MPZ . Correlation was high between firefly and Nano‐luciferase reporters and between both reporters and ER localization. UPR activity did not correlate with clinical onset or severity. Conclusion Many CMT 1B causing mutations activate the UPR and may be susceptible to therapeutic efforts to facilitate UPR function.